drugset / Trial / NCT00975754

Lung Deposition Via Different Inhalation Devices

NCT00975754

Phase 1 Completed 16 enrolled AstraZeneca
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to assess the deposition of budesonide to the lung after inhalation with 5 different devices and to relate the findings to in vitro properties of inhaled budesonide.

Timeline

Start
2009-09
Primary completion
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 160 ug Inhaled
Subject Budesonide Small molecule 200 ug Inhaled
Subject Budesonide Small molecule 0.5 mg/ml Inhaled

Indications

No indication recorded.